Danicopan study for PNH in Korea
Part of Blood & lymphatic clinical trials.
This trial is studying danicopan as an add-on therapy for people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking a C5 inhibitor like eculizumab or ravulizumab. It aims to see how well danicopan works when used together with these standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of PNH (a rare blood disorder).
- You are currently being treated with a C5 inhibitor (eculizumab or ravulizumab).
- You are eligible to add danicopan to your current treatment.
- You or your legal representative must sign a consent form agreeing to participate.
- You cannot be in any other interventional research study during this trial.
- Danicopan must be used only for its approved indication in Korea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding danicopan to a standard treatment (ravulizumab or eculizumab) for children with PNH who still have anemia from extravascular hemolysis. The goal is to see if the combination helps improve red blood cell counts.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This Phase 3 study tests whether long-term treatment with pozeli(z)umab plus cemdisiran is safe and works well in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is mainly for people whose PNH does not respond to certain standard medicines or who have genetic changes that make them refractory.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.